Skip to main content
Top
Published in: Diabetologia 11/2006

01-11-2006 | Article

Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling

Authors: M. Möhlig, A. Flöter, J. Spranger, M. O. Weickert, T. Schill, H. W. Schlösser, G. Brabant, A. F. H. Pfeiffer, J. Selbig, C. Schöfl

Published in: Diabetologia | Issue 11/2006

Login to get access

Abstract

Aims/hypothesis

Polycystic ovary syndrome (PCOS) is a risk factor of type 2 diabetes. Screening for impaired glucose metabolism (IGM) with an OGTT has been recommended, but this is relatively time-consuming and inconvenient. Thus, a strategy that could minimise the need for an OGTT would be beneficial.

Materials and methods

Consecutive PCOS patients (n=118) with fasting glucose <6.1 mmol/l were included in the study. Parameters derived from medical history, clinical examination and fasting blood samples were assessed by decision tree modelling for their ability to discriminate women with IGM (2-h OGTT value ≥7.8 mmol/l) from those with NGT.

Results

According to the OGTT results, 93 PCOS women had NGT and 25 had IGM. The best decision tree consisted of HOMA-IR, the proinsulin:insulin ratio, proinsulin, 17-OH progesterone and the ratio of luteinising hormone:follicle-stimulating hormone. This tree identified 69 women with NGT. The remaining 49 women included all women with IGM (100% sensitivity, 74% specificity to detect IGM). Pruning this tree to three levels still identified 53 women with NGT (100% sensitivity, 57% specificity to detect IGM). Restricting the data matrix used for tree modelling to medical history and clinical parameters produced a tree using BMI, waist circumference and WHR. Pruning this tree to two levels separated 27 women with NGT (100% sensitivity, 29% specificity to detect IGM). The validity of both trees was tested by a leave-10%-out cross-validation.

Conclusions/interpretation

Decision trees are useful tools for separating PCOS women with NGT from those with IGM. They can be used for stratifying the metabolic screening of PCOS women, whereby the number of OGTTs can be markedly reduced.
Literature
1.
go back to reference Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749PubMedCrossRef Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749PubMedCrossRef
2.
go back to reference Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800PubMedCrossRef Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800PubMedCrossRef
4.
go back to reference Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434–2438PubMedCrossRef Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434–2438PubMedCrossRef
5.
go back to reference Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078–3082PubMedCrossRef Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078–3082PubMedCrossRef
6.
go back to reference Pasquali R, Gambineri A, Biscotti D et al (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767–2774PubMedCrossRef Pasquali R, Gambineri A, Biscotti D et al (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767–2774PubMedCrossRef
7.
go back to reference Harborne L, Fleming R, Lyall H, Sattar N, Norman J (2003) Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88:4116–4123PubMedCrossRef Harborne L, Fleming R, Lyall H, Sattar N, Norman J (2003) Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88:4116–4123PubMedCrossRef
8.
go back to reference Haas DA, Carr BR, Attia GR (2003) Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril 79:469–481PubMedCrossRef Haas DA, Carr BR, Attia GR (2003) Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril 79:469–481PubMedCrossRef
9.
go back to reference Costello MF, Eden JA (2003) A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79:1–13PubMedCrossRef Costello MF, Eden JA (2003) A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79:1–13PubMedCrossRef
10.
go back to reference Ronnemaa T, Laakso M, Pyorala K, Kallio V, Puukka P (1991) High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 11:80–90PubMed Ronnemaa T, Laakso M, Pyorala K, Kallio V, Puukka P (1991) High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 11:80–90PubMed
11.
go back to reference Skarfors ET, Selinus KI, Lithell HO (1991) Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 303:755–760PubMedCrossRef Skarfors ET, Selinus KI, Lithell HO (1991) Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 303:755–760PubMedCrossRef
12.
go back to reference Zimmet P, Dowse G, Bennett P (1991) Hyperinsulinaemia is a predictor of non-insulin-dependent diabetes mellitus. Diabetes Metab 17:101–108 Zimmet P, Dowse G, Bennett P (1991) Hyperinsulinaemia is a predictor of non-insulin-dependent diabetes mellitus. Diabetes Metab 17:101–108
13.
go back to reference The Rotterdam Consensus Workshop (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef The Rotterdam Consensus Workshop (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef
14.
go back to reference Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146PubMed Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146PubMed
15.
go back to reference Gambineri A, Pelusi C, Manicardi E et al (2004) Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 53:2353–2358PubMed Gambineri A, Pelusi C, Manicardi E et al (2004) Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 53:2353–2358PubMed
16.
go back to reference Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169PubMedCrossRef Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169PubMedCrossRef
17.
go back to reference Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A (2002) Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87:1017–1023PubMedCrossRef Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A (2002) Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87:1017–1023PubMedCrossRef
18.
go back to reference Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ (2001) Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16:1995–1998PubMedCrossRef Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ (2001) Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16:1995–1998PubMedCrossRef
19.
go back to reference American Diabetes Association (2002) Clinical practice recommendations 2002. Diabetes Care 25 (Suppl 1):S21–S24 American Diabetes Association (2002) Clinical practice recommendations 2002. Diabetes Care 25 (Suppl 1):S21–S24
20.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef
21.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
22.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
23.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
24.
go back to reference Garzotto M, Beer TM, Hudson RG et al (2005) Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 23:4322–4329PubMedCrossRef Garzotto M, Beer TM, Hudson RG et al (2005) Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 23:4322–4329PubMedCrossRef
25.
go back to reference Dennis JL, Hvidsten TR, Wit EC et al (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11:3766–3772PubMedCrossRef Dennis JL, Hvidsten TR, Wit EC et al (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11:3766–3772PubMedCrossRef
26.
go back to reference El-Serag HB, Mallat DB, Rabeneck L (2005) Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Clin Gastroenterol 39:152–159PubMed El-Serag HB, Mallat DB, Rabeneck L (2005) Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Clin Gastroenterol 39:152–159PubMed
27.
go back to reference Beerenwinkel N, Schmidt B, Walter H et al (2002) Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 99:8271–8276PubMedCrossRef Beerenwinkel N, Schmidt B, Walter H et al (2002) Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 99:8271–8276PubMedCrossRef
28.
go back to reference Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP (2005) Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54:333–339PubMed Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP (2005) Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54:333–339PubMed
29.
go back to reference Spranger J, Möhlig M, Wegewitz U et al (2004) Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 61:738–746CrossRef Spranger J, Möhlig M, Wegewitz U et al (2004) Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 61:738–746CrossRef
30.
go back to reference Möhlig M, Spranger J, Osterhoff M et al. (2004) The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150:525–532PubMedCrossRef Möhlig M, Spranger J, Osterhoff M et al. (2004) The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150:525–532PubMedCrossRef
31.
go back to reference Schöfl C, Horn R, Schill T, Schlösser HW, Müller MJ, Brabant G (2002) Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 87:4607–4610PubMedCrossRef Schöfl C, Horn R, Schill T, Schlösser HW, Müller MJ, Brabant G (2002) Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 87:4607–4610PubMedCrossRef
32.
go back to reference Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G (eds) Current issues in endocrinology and metabolism: polycystic ovary syndrome. Blackwell, New York, pp 377–384 Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G (eds) Current issues in endocrinology and metabolism: polycystic ovary syndrome. Blackwell, New York, pp 377–384
33.
go back to reference Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192PubMed Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192PubMed
34.
go back to reference Rudenski AS, Matthews DR, Levy JC, Turner RC (1991) Understanding “insulin resistance”: both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 40:908–917PubMedCrossRef Rudenski AS, Matthews DR, Levy JC, Turner RC (1991) Understanding “insulin resistance”: both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 40:908–917PubMedCrossRef
35.
go back to reference World Health Organization (2002) Laboratory diagnosis and monitoring of diabetes mellitus. WHO, Geneva, pp 1–26 World Health Organization (2002) Laboratory diagnosis and monitoring of diabetes mellitus. WHO, Geneva, pp 1–26
36.
go back to reference Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef
37.
go back to reference Quinlan JR (1993) C4.5 programs for machine learning. Morgan Kaufmann, San Mateo, USA Quinlan JR (1993) C4.5 programs for machine learning. Morgan Kaufmann, San Mateo, USA
38.
go back to reference Breiman L, Freidman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Wadsworth International Group, Belmont, USA Breiman L, Freidman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Wadsworth International Group, Belmont, USA
39.
go back to reference Clark LA, Pregibon D (1997) Tree-based models. In: Venables WN, Ripley BD (eds) Modern applied statistics with S-PLUS. Springer-Verlag, New York, USA Clark LA, Pregibon D (1997) Tree-based models. In: Venables WN, Ripley BD (eds) Modern applied statistics with S-PLUS. Springer-Verlag, New York, USA
40.
go back to reference Azuaje F (2003) Genomic data sampling and its effect on classification performance assessment. BMC Bioinformatics 4:5PubMedCrossRef Azuaje F (2003) Genomic data sampling and its effect on classification performance assessment. BMC Bioinformatics 4:5PubMedCrossRef
41.
go back to reference Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A (2001) Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 75:177–184PubMedCrossRef Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A (2001) Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 75:177–184PubMedCrossRef
42.
go back to reference Harris MI, Hadden WC, Knowler WC, Bennett PH (1987) Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 36:523–534PubMed Harris MI, Hadden WC, Knowler WC, Bennett PH (1987) Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 36:523–534PubMed
43.
go back to reference Robbins DC, Andersen L, Bowsher R et al (1996) Report of the American Diabetes Association’s Task Force on standardization of the insulin assay. Diabetes 45:242–256PubMed Robbins DC, Andersen L, Bowsher R et al (1996) Report of the American Diabetes Association’s Task Force on standardization of the insulin assay. Diabetes 45:242–256PubMed
44.
go back to reference Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495PubMed Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495PubMed
45.
go back to reference Mykkanen L, Haffner SM, Hales CN, Ronnemaa T, Laakso M (1997) The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 46:1990–1995PubMed Mykkanen L, Haffner SM, Hales CN, Ronnemaa T, Laakso M (1997) The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 46:1990–1995PubMed
46.
go back to reference Pfützner A, Kunt T, Hohberg C et al (2004) Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27:682–687PubMed Pfützner A, Kunt T, Hohberg C et al (2004) Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27:682–687PubMed
47.
go back to reference Ludvik B, Nolan JJ, Baloga J, Sacks D, Olefsky J (1995) Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 44:1121–1125PubMed Ludvik B, Nolan JJ, Baloga J, Sacks D, Olefsky J (1995) Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 44:1121–1125PubMed
48.
go back to reference Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL (2003) Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46:625–633PubMed Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL (2003) Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46:625–633PubMed
Metadata
Title
Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling
Authors
M. Möhlig
A. Flöter
J. Spranger
M. O. Weickert
T. Schill
H. W. Schlösser
G. Brabant
A. F. H. Pfeiffer
J. Selbig
C. Schöfl
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0395-0

Other articles of this Issue 11/2006

Diabetologia 11/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.